SARS-CoV-2 neutralizing antibodies in patients with varying severity of acute COVID-19 illness.
SARS-CoV-2 neutralizing antibodies in patients with varying severity of acute COVID-19 illness.
复制标题
DOI：
10.1038/s41598-021-81629-2
复制
发表时间：
2021-01-21
影响因子：
4.6
通讯作者：
Malavige GN
中科院分区：
文献类型：
--
作者：
Jeewandara C;Jayathilaka D;Gomes L;Wijewickrama A;Narangoda E;Idampitiya D;Guruge D;Wijayamuni R;Manilgama S;Ogg GS;Tan CW;Wang LF;Malavige GN
为了支持疫苗开发，并帮助恢复期血浆治疗，了解SARS-CoV-2中和抗体（NAb）的动力学，时间和持久性及其与临床疾病严重程度的关系将是重要的。因此，我们使用替代病毒中和试验来评价不同疾病严重程度患者、长期脱落患者和不同时间点轻度/无症状疾病患者的病毒中和水平。与轻度或无症状疾病患者相比，重度或中度COVID-19疾病患者出现NAb的时间更早，水平更高。此外，那些延长病毒脱落的人，NAB出现的速度更快，水平更高，而不是那些更早清除病毒的人。在患病的第一周，轻度疾病患者的NAb水平显著低于中度和重度疾病患者（p = 0.01）。在4周（28天）结束时，尽管89%的患者有NAb，但在> 90天的患者中，38/76（50%）的NAb结果为阴性。与发病后4至8周相比，抗体水平在恢复期（发病后> 90天）显著下降。我们的数据显示，早期疾病期间高水平的NAb与临床疾病的严重程度相关，并且这些抗体在发病3个月后在50%的个体中下降。
In order to support vaccine development, and to aid convalescent plasma therapy, it would be important to understand the kinetics, timing and persistence of SARS-CoV-2 neutralizing antibodies (NAbs), and their association with clinical disease severity. Therefore, we used a surrogate viral neutralization test to evaluate their levels in patients with varying severity of illness, in those with prolonged shedding and those with mild/asymptomatic illness at various time points. Patients with severe or moderate COVID-19 illness had earlier appearance of NAbs at higher levels compared to those with mild or asymptomatic illness. Furthermore, those who had prolonged shedding of the virus, had NAbs appearing faster and at higher levels than those who cleared the virus earlier. During the first week of illness the NAb levels of those with mild illness was significantly less (p = 0.01), compared to those with moderate and severe illness. At the end of 4 weeks (28 days), although 89% had NAbs, 38/76 (50%) in those with > 90 days had a negative result for the presence of NAbs. The Ab levels significantly declined during convalescence (> 90 days since onset of illness), compared to 4 to 8 weeks since onset of illness. Our data show that high levels of NAbs during early illness associated with clinical disease severity and that these antibodies declined in 50% of individuals after 3 months since onset of illness.
登录
查看更多内容
DOI：
10.15557/pimr.2020.0003
发表时间：
2020-01-01
影响因子：
3.6
作者：
通讯作者：
--
DOI：
10.1007/s10096-004-1271-9
发表时间：
2005-01
期刊：
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
影响因子：
--
作者：
Cheng Y;Wong R;Soo YO;Wong WS;Lee CK;Ng MH;Chan P;Wong KC;Leung CB;Cheng G
通讯作者：
Cheng G
影响因子：
7.3
作者：
Fierz, Walter;Walz, Brigitte
通讯作者：
Walz, Brigitte
影响因子：
19
作者：
Harvala, Heli;Mehew, Jennifer;Zambon, Maria
通讯作者：
Zambon, Maria
影响因子：
11.8
作者：
Payne DC;Iblan I;Rha B;Alqasrawi S;Haddadin A;Al Nsour M;Alsanouri T;Ali SS;Harcourt J;Miao C;Tamin A;Gerber SI;Haynes LM;Al Abdallat MM
通讯作者：
Al Abdallat MM